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ABSTRACT 
Objective: To develop a novel, accurate, precise and linear reverse phase high performance liquid chromatographic (RP-HPLC) method for 
simultaneous quantitative estimation of ramipril, atorvastatin and clopidogrel in Atamra-CV tablet and validate as per international conference on 
harmonization (ICH) guidelines and to perform the force degradation studies using the developed method. 
Methods: In the present work, the good chromatographic separation was achieved isocratically using a shim-pack HPLC Kromasil 150 mm x 4.6 
mm, 5 m. µ. And mobile phase consisting of 0.05 M potassium dihydrogen orthophosphate pH 3 adjusted with orthophosphoric acid and acetonitrile 
in the ratio (52:48), at flow rate 1 ml/min and column temperature (30 °C). The effluents obtained were monitored at 210 nm with the UV-visible 
detector. 
Results: The retention time of ramipril, atorvastatin and clopidogrel was found to be 2.893 min, 5.012 min and 6.102 min respectively. The linearity 
of ramipril, atorvastatin and clopidogrel was found in the range of 25-150 % and the correlation coefficient for ramipril, atorvastatin and 
clopidogrel were>0.999. The high recovery values (98%-101%) indicate a satisfactory accuracy. The low percent relative standard deviation (% 
RSD) values in the precision study reveals that the method is precise. The three-drug samples were subjected to stress conditions of acidic and 
alkaline hydrolysis, oxidation, photolysis and thermal degradation. The proposed method proved to be stability-indicating by resolution of the 
analytes from their forced-degradation products. 
Conclusion: The developed method is novel, simple, precise, rapid, accurate and reproducible for simultaneous estimation of ramipril, atorvastatin 
and clopidogrel tablet dosage form. Hence the proposed method may find practical applications as a quality-control tool in the simultaneous 
analysis of the three drugs in combined dosage forms in quality-control laboratories. The proposed method was made use of photodiode array 
(PDA) as a tool for peak identification and purity confirmation.  
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Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, used to 
treat hypertension and congestive heart failure. It acts on the renin-
angiotensin system [1-2]. Ramipril is an anti-hypertensive agent [3-4] 
and chemically (1 S, 5S, 7S)-8-[(2S)-2-[[(IS)-1-ethoxycarbonyl-3-
phenylpropvl] amino] propanovl]-8-azabicvclo [33O] octane-7-
carboxylic acid [5-8]. It blocks the counter-regulatory rise in 
Angiotensin-II triggered by diuretic theory [9-10]. The structure of 
ramipril was shown in (fig. 1a) Atorvastatin calcium is a selective, 
competitive HMG-CoA reductase inhibitor [11-12], is used to lower 
cholesterol and triglycerides in patients with hypercholesterolemia 
and mixed dyslipidemia and in the treatment of homozygous familial 
hypercholesterolemia [7]. It is chemically known as (βR, 8R)-2-(4-
fluorophenyl)-α, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenyl 
amino) carbonyl] 1H-pyrrole-1-heptanoic acid trihydrate [13-14]. It 
lowers lipid levels by inhibiting HMG-CoA reductase, a rate-limiting 
enzyme in cholesterol biosynthesis in the liver, thus reducing the 
cholesterol content in hepatocytes [15]. Antihypertensive and lipid-
lowering medications substantially reduce the risk of stroke, coronary 
artery disease (CAD), and death in patients with cardiovascular risk 
factors [16-17]. Clopidogrel bisulfate is chemically (+)-(S)-(2-
chlorophenyl)-6,7-dihydrothieno [3,2-c] pyridine-5 (4H) acetic acid 
methyl ester sulphate is a potent oral antiplatelet agent often used for 
the treatment of CAD, peripheral vascular disease (PVD) and 
cerebrovascular diseases (CVD). Since it is a prodrug, it must be 
metabolized by CYP450 enzymes to produce the active metabolite that 
inhibits platelet aggregation. This active metabolite selectively inhibits 
adenosine diphosphate (ADP) binding to its platelet P2Y12 receptor 
and subsequently the ADP-mediated activation of the glycoprotein 
GPIIb/IIIa complex, thereby inhibiting platelet aggregation [18-20].  
 
 
Fig. 1: Chemical structure of (a) Ramipril (b) Atorvastatin (c) Clopidogrel 
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As per the literature survey several methods have been reported for 
the estimation of ramipril, atorvastatin, and clopidogrel individually 
or with the combination of some other drugs. Some of the methods 
were being; simultaneous estimation of atorvastatin, clopidogrel 
[21-22] ramipril, atorvastatin [23-24]. There is no official method 
for this combination so far as per our knowledge. The present 
proposed method estimates ramipril, atorvastatin, and clopidogrel 
in a simple and economical process. The main aim of this method 
was to determine and validate the ramipril, atorvastatin and 
clopidogrel based on International Conference on Harmonization 
[25-27] guidelines. This method was made use of a reproducible 
procedure for the quantitative analysis of drug samples as the bulk 
drug and in tablet dosage forms. The designed method was 
considered as an advisable to develop precise, accurate, a simple RP-
HPLC method for stability indicating and simultaneous estimation of 
ramipril, atorvastatin and clopidogrel in tablets. 
MATERIALS AND METHODS 
Instrumentation  
The analysis was performed on an HPLC instrument used was of 
Kromasil 150 mm x 4.6 mm, 5 m. µ. With Auto-Injector and PDA 
Detector and it was controlled by using software Empower 2. and it 
has UV-VIS spectrophotometer PG Instruments T60 with a special 
bandwidth of 2 mm and 10 mm and matched quartz was be used for 
measuring absorbance for ramipril, atorvastatin and clopidogrel 
solutions. The separation and quantization were made on column 
(Kromasil 150 mm x 4.6 mm, 5 mµ). 
Materials 
HPLC grade acetonitrile, water was secured from Ranbaxy, India, 
and orthophosphoric acid AR grade was purchased from SD Fine 
Chem. Mumbai, India were used in the study and supported by the 
literature. The drug samples were kindly supplied by Spectrum 
Pharmaceuticals Pvt Ltd, Kukutpally, Hyderabad, India, and the 
formulation samples analytical grade of orthophosphoric acid, 
sodium hydroxide, hydrochloric acid, hydrogen peroxide and high 
purity distilled water were used. The preparation of three drugs was 
Atamra-CV tablets labeled claim was 5 mg of ramipril, 10 mg of 
atorvastatin and 75 mg of clopidogrel. 
General procedure 
Chromatographic conditions 
A mobile phase system consisting of buffer and acetonitrile was used 
in the ratio of 52:48A % V/V at a pH 3 adjusted with orthophosphoric 
acid and water and methanol in the ratio of 50:50 V/V used as diluents 
for preparing the working solutions of drug. The separation was 
achieved with the elution method. The flow rate was 1.0 ml/min. The 
injection volume was 10 ml. The eluant was monitored by the photo 
diode array detector (PDA) from 200 to 400 nm, and chromatograms 
were extracted at the wavelengths of 210 nm. The total run time was 
11 min, and all establishments were performed at 30 °C. 
Standard solutions 
Accurately Weighed and transferred 6 mg, 6 mg and 18 mg of 
ramipril, atorvastatin and clopidogrel working Standards into a 50 
ml, 25 ml and 10 ml clean dry volumetric flask, add 5 ml of diluents, 
sonicated for 30 min and made up to the final volume with diluents 
to obtain the concentrations of 12 µg/ml ramipril, 24 µg/ml 
atorvastatin and 180 µg/ml of clopidogrel. 
From the above stock solutions, 1 ml was pipette out in to a 10 ml 
volumetric flask and then made up to the final volume with diluents 
and achieved concentrations 12, 24 and 180 µg/ml. Three injections 
were finished for each concentration and chromatographs were 
gained under the previously described liquid chromatographic 
conditions. The peak areas were plotted in opposition to the 
consequent concentrations to erect the calibration graphs. 
Assay of sample preparation 
Six Atamra-CV tablets were weighed and calculated the average 
weight of each tablet then the weight equivalent to 1 tablet was 
transferred into a 100 ml volumetric flask, 70 ml of diluents added 
and sonicated for 30 min, further the volume made up with diluents 
and filtered. From the filtered solution 0.4 ml was pipette out into a 
10 ml volumetric flask and made up to10 ml with diluents and 
acquired final concentrations were 12, 24 and 180 µg/ml for 
ramipril, atorvastatin and clopidogrel respectively. These specified 
concentrations were used for general procedure and recovered 
concentrations were calculated from the consequent calibration 
graphs. For regular addition assay, test solutions were spiked with 
aliquots of regular solutions of the three compounds to gain total 
concentrations contained by the earlier specified ranges then 
treated as under common process. Recovered concentrations were 
deliberated by assimilating the analyte response with the growth 
response achieved after addition of the standard. 
Method validation procedure 
The method was validated as per ICH guidelines [25-27]. The 
different validation parameters which were performed are 
following: system suitability, linearity, precision, accuracy, 
specificity, and limit of detection, limit of quantification, robustness, 
degradation studies and the stability indicating capability. 
Stability-indicating and forced degradation studies 
Forced degradation studies were executed on ramipril, atorvastatin 
and clopidogrel standards based on the following conditions:  
Oxidation 
To 1 ml of stock solution of ramipril, atorvastatin and clopidogrel 
and 1 ml of 20% hydrogen peroxide (H2O2
Acid degradation studies 
) were added separately. 
The solutions were kept for 30 min at 60 °C. For HPLC study, the 
resultant solution was diluted to obtain concentrations 12, 24 
and184 µg/ml. A solution of 10 µl was injected into the system and 
the chromatograms were recorded to assess the stability of sample. 
To 1 ml of stock solution of ramipril, atorvastatin and clopidogrel and 
1 ml of 2N Hydrochloric acid was added and refluxed for 30 min at 60 
°C. The resultant solution was diluted to obtain concentrations 12, 24 
and 184 µg/ml. A solution of 10 µl was injected into the system and 
the chromatograms were recorded to assess the stability of sample. 
Alkali degradation studies 
To 1 ml of stock solution of ramipril, atorvastatin and clopidogrel 
and 1 ml of 2N sodium hydroxide was added and refluxed for 30 min 
at 60 °C. The resultant solution was diluted to obtain concentrations 
12 µg/ml, 24 µg/ml and 184 µg/ml. A solution of 10 µl was injected 
into the system and the chromatograms were recorded to assess the 
stability of sample. 
Dry heat degradation studies 
The standard stock solution was placed in oven at 105 °C for 6 h to 
study dry heat degradation. For HPLC study, the resultant solution 
was diluted to obtain concentrations 12 µg/ml, 24 µg/ml and 184 
µg/ml for ramipril, atorvastatin and clopidogrel. A solution of 10 µl 
was injected into the system and the chromatograms were recorded 
to assess the stability of the sample. 
Photo stability studies 
The photochemical stability of the drugs were also studied by exposing 
the concentrations of 12 µg/ml, 24 µg/ml and 184 µg/ml solution to 
UV Light by keeping the beaker in UV Chamber for 7 d or 200 Watt 
hours/m2in photostability chamber. For HPLC study, the resultant 
solution was diluted to obtain 12 µg/ml, 24 µg/ml and 184 µg/ml 
concentrated solutions and 10 µl were injected into the system and the 
chromatograms were recorded to assess the stability of the sample. 
Neutral degradation studies 
Stress testing under neutral conditions was studied by refluxing the 
drugs in water for 6 h at a temperature of 60°C. For HPLC study, the 
resultant solution was diluted to 12 µg/ml, 24 µg/ml and 184 µg/ml 
concentrated solutions and 10 µl were injected into the system and 
the chromatograms were recorded to assess the stability of the 
sample. 
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RESULTS AND DISCUSSION 
A simple, rapid and precise method has been developed and 
validated for the drug ramipril, atorvastatin and clopidogrel. There 
is no official method for this combination so far. However, few 
methods have been reported in either of one or two in this 
combination with some other drugs. On comparison with literature, 
it is found that Mobile phase used by SM Patole et al. [6] used 
methanol and acetate buffer. Rajesh Sharma et al. [7] Gurupadayya 
et al. [18] were phosphate buffer and acetonitrile methanol. Nitin 
dubey et al. [28] used methanol, acetonitrile and water. 
Sahityasundar et al. [29] used acetonitrile, methanol and 
trimethylamine. The buffers in the mobile phases used in all the 
methods take more preparation time and also the usage of buffers 
reduces the life of column. The retention time of drugs in the 
methods developed by SM Patole et al. [6] 5.80 min for ramipril and 
8.20 min for atorvastatin. Rajesh Sharma et al. [7] 3.620 and 11.710 
min for ramipril and atorvastatin. Gurupadayya et al. [18] 8.2 min 
for clopidogrel. Nitin dubey et al. [28] 11.820 min for clopidogrel 
and 15.620 min for atorvastatin. Sahityasundar et al. [29] 3.8 min for 
atorvastatin and 7.4 min for clopidogrel thereby increasing the 
analysis time.  
In the proposed method a simple mobile phase consisting of buffer 
and acetonitrile was used which elute the ramipril, atorvastatin and 
clopidogrel with lower retention time. The retention times were 
2.903 min, 5.005 min and 6.134 for ramipril, atorvastatin and 
clopidogrel respectively. The calibration curve was linear over the 
concentration range of 25-150 ppm. The LOD values were 0.29, 0.35 
and1.97 and LOQ values were found to be 0.89, 1.07 and 5.98 for 
ramipril, atorvastatin and clopidogrel respectively. The high 
percentage of recovery and low percentage coefficient of variance 
confirm the suitability of the method and the forced degradation 
studies shows that the developed method was stability indicating. 
Hence it was concluded that the RP-HPLC method developed was 
highly suitable for routine analysis and all the parameters result 
data was shown in method validation systematically.  
Method development 
Six trials were performed for the method development and the best 
peaks with least fronting factor was elevated for ramipril, 
atorvastatin and clopidogrel to be with retention times were 2.903, 
5.005, 6.134 min respectively. The resultant chromatogram revealed 
in the fig. 2. 
 
 
Fig. 2: Sample chromatogram of ramipril, atorvastatin and clopidogrel 
 
 
Fig. 3: Standard chromatogram of ramipril, atorvastatin and clopidogrel 
 
Method validation 
System suitability test 
Six replicate injections of standard solutions were injected and the 
chromatograms were recorded. The system was suitable for analysis 
of ramipril, atorvastatin and clopidogrel if the % relative standard 
deviation (% RSD) of area counts in six repeated injections should 
be not more than 2.0%. USP tailing factor for ramipril, atorvastatin 
and clopidogrel peak should be not more than 2.0. USP resolution 
factor between the peaks corresponding to ramipril, atorvastatin 
and clopidogrel should be more than 2.0. The results are shown in 
the table 1. 
 
Table 1: System suitability results 
Parameter Ramipril Atorvastatin Clopidogrel 
USP tailing Factor 1.07 0.96 0.93 
USP plate count 1391 3899 4037 
LOD(µg/ml) 0.29 0.35 1.97 
LOQ(µg/ml) 0.89 1.07 5.98 
% RSD 0.7 0.6 0.5 
Balaswami et al. 
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Linearity and concentration ranges 
Working dilutions of ramipril, atorvastatin and clopidogrel was 25 
to 150 % was prepared by taking suitable aliquots of solutions of 
drug in several 10 ml volumetric flask and made up to the mark with 
mobile phase and those are depicted in table 2. 10 μl amount of 
every dilution was injected in to the column with a flow rate of 1 
ml/min. The samples in elute were monitored at 210 nm and the 
subsequent chromatograms were recorded. From these, calculated 
the mean peak areas and showed in table-3 for ramipril, atorvastatin 
and clopidogrel a plot of concentration vs peak areas was produced 
and drawn in the fig. 4, 5 and 6. The regression of the plot was 
calculated by least square regression method. Regression equation 
of ramipril was y = 17045x+1518 (R² = 0.999), atorvastatin was y = 
21828x+2328 (R2=0.999) clopidogrel was y = 13555x+8103 
(R2
 
=0.999) and also the results were presented in table 3. 




stock (ml)  
Volume of 
flask (ml) 
Concentration in ppm 
(ramipril) 
Concentration in ppm 
(Atorvastatin) 




1 0.25 10 3 6 45 25 
2 0.5 10 6 12 90 50 
3 0.75 10 9 18 135 75 
4 1 10 12 24 180 100 
5 1.25 10 15 30 225 125 
6 1.5 10 18 36 270 150 
 
Table 3: linearity peak area values of ramipril, atorvastatin and clopidogrel 
S. No. concentration Peak areas of ramipril Peak areas of atorvastatin Peak areas of clopidogrel 
1 25 56110 134192 630356 
2 50 103767 262687 1241964 
3 75 156441 399126 1845601 
4 100 201249 527033 2406287 
5 125 254148 659598 3049912 
6 150 312733 783975 3691858 
 
 
Fig. 3: Linearity graph for ramipril 
 
 
Fig. 4: Linearity graph for atorvastatin 
 
 
Fig. 5: Linearity graph for clopidogrel, X-Axis = Concentration, Y-Axis = peak area 
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The standard ramipril, atorvastatin and clopidogrel solutions were 
injected for six times and measured the area for all six trails in RP-
HPLC. The %RSD for the area of six repeat injections was founded to 
be within the specific limits. The data of system precision was shown 
in the table 4, repeatability was presented in table 5, and inter day 
precision was showed in table 6. 
Acceptance Criteria: The % RSD should not be more than 2% 
 
Table 4: Precision results of system 
S. No. Area of ramipril Area of atorvastatin Area of clopidogrel 
1 208249 524974 2406287 
2 207249 522689 2495508 
3 209523 528939 2499346 
4 209845 522427 2486225 
5 206360 520971 2527346 
6 208360 527033 2517161 
Mean 208264 524506 2488646 
SD 1322.8 3045.5 43037.7 
%RSD 0.64 0.58 1.73 
n=6; SD denotes for standard deviation; RSD denotes for relative standard deviation. 
 
Table 5: Repeatability results 
S. No. Area of ramipril Area of atorvastatin Area of clopidogrel 
1 210787 516694 2519164 
2 209879 530243 2509185 
3 208496 530243 2499346 
4 206680 520780 2460405 
5 208144 522780 2477286 
6 210602 523716 2482551 
Mean 209098 524076 2491323 
S. D 1463.1 5352.2 21856.1 
%RSD 0.70 1.02 0.88 
n=6; SD denotes for standard deviation; RSD denotes for relative standard deviation. 
 
Table 6: Inter day precision results 
S. No. Area of ramipril Area of atorvastatin Area of clopidogrel 
1 210502 512725 2547431 
2 210637 509879 2578002 
3 213167 51784401 2593673 
4 209196 528881 2548908 
5 212468 514777 2579421 
6 212764 521027 2546590 
Mean 211456 517522 2565671 
SD 1571.7 6787.9 20508.6 
%RSD 0.7 1.3 0.8 
n=6; SD denotes for standard deviation; RSD denotes for relative standard deviation. 
 
Accuracy 
Accuracy of the readings was computed by % recovery of six different 
concentrations of ramipril, atorvastatin and clopidogrel at 50%, 100% 
and 150% and also standard addition technique was carried out for 
same samples. The results acquired including the means of the 
recovery and standard deviations were displayed in table 7. 
Acceptance Criteria: The % Recovery for ramipril, atorvastatin and 
clopidogrel at each stage should be between 99 to 101%. 
  
Table 7: Accuracy expressed as % recovery of three drugs by the proposed method 
 Ramipril Atorvastatin Clopidogrel 
% Concentration 50 100 150 50 100 150 50 100 150 
Trail-I 101.07 100.65 99.80 99.53 99.54 99.63 100.84 99.80 100.15 
Trail-II 99.78 100.12 100.11 99.03 99.69 100.07 99.71 99.50 100.13 
Trail-III 99.81 100.18 100.58 100.52 100.44 100.22 98.32 100.35 99.60 
AVG (% recovery) 100.22 100.32 100.17 99.70 99.89 99.97 99.62 99.88 99.96 
SD 0.74 0.29 0.39 0.76 0.48 0.31 1.26 0.43 0.31 
%RSD 0.74 0.29 0.39 0.76 0.48 0.31 1.26 0.43 0.31 
n=3; AVG denotes average; SD denotes for standard deviation; RSD denotes for relative standard deviation 
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To estimate the accuracy and precision of the proposed method 
recovery studies were carried out. A fixed amount of sample was taken 
and reference drugs were added at 50%, 100% and 150% levels. The 
results were analyzed and the results were within the limits. 
Specificity 
The specificity of the RP-HPLC method is furnished, where complete 
separations of ramipril, atorvastatin and clopidogrel were 
distinguished in presence of other inert excipients used in tablets. In 
addition, there was no deterrence at the retention time of in the 
chromatogram of placebo solution. In the case of peak purity 
analysis with PDA, purity gradient was always not greater than 
purity threshold for the analytes. This shown that the peaks of 
analyte were pure and excipients in the formulation does not 
interfere the analyte. The data were listed in the table 8. 
Limit of detection and limit of quantification 
Limit of Detection (LOD) is the least concentration of an analyte in a 
sample that can be identified but not quantified. LOD is indicated as 
a concentration at a précised signal to noise ratio. The LOD will 
depend on the procedure of analysis along with type of instrument. 
In the chromatography, detection limit is the injected quantity that 
consequences in a peak with a height at least thrice or twice as high 
as baseline noise level. LOD was computed by using formula 
LOD = 3.3 (SD
S
) 
The LOD was found to be 0.29, 0.35 and 1.97 for ramipril, 
atorvastatin and clopidogrel respectively. 
Limit of quantification (LOQ) is defined as least concentration of 
analyte in a sample that can be estimated with tolerable precision, 
accuracy and reliability by a specified method under affirmed 
experimental conditions. LOQ is uttered as a concentration at a 
specified signal to noise ratio. In the chromatography, limit of 
quantification is the injected quantity that consequences in a peak 
with a height, ten times as high as base line noise level. LOQ is 
calculated by using the formula LOQ = 10 (SD
S
) 
The LOQ was found to be 0.89, 1.07 and 5.98 for ramipril, 
atorvastatin and clopidogrel respectively. 
Robustness 
Robustness is denoted by making speculate changes in the 
chromatographic conditions like change in temperature, mobile 
phase composition and flow rate were assessed for the impact on 
the present method. It was founded from the chromatograms that 
the results were not exceeding the limits. This represents that the 
method developed is robust and shown in the table 9. 
 
Table 8: Specificity results for ramipril, atorvastatin and clopidogrel 
S. No. Name of the sample No. of injections  Area of ramipril Area of atorvastatin Area of clopidogrel 
1 Blank 1 - - - 
2 Placebo 1 - - - 
3 Standard 1 208249 524974 2406287 
4 Water sample 1 206846 512140 2502060 
 
Table 9: Robustness of ramipril, atorvastatin and clopidogrel 
Parameter Ramipril Atorvastatin  Clopidogrel 
Temperature±5 25 204346 496627 2424942 
35 206505 491383 2421334 
Flow rate±0.1 0.9 203495 486072 2407038 
1.1 202758 481871 2413933 
Mobile Phase change±5 48:52 200842 482383 2418510 
57:53 201772 481680 2409303 
 
Degradation studies 
The forced degradation studies were conceded out to ensure the 
effective separation of ramipril, atorvastatin and clopidogrel in the 
current study from degradation products. The degradation was 
observed by reducing the peak areas of the drug substances with same 
drug molecules of degraded peak areas. The percentage assay of 
degradation was calculated from the peak area obtained in degradation 
conditions and it was compared with assay of nondegraded conditions. 
The percentage assay degradation in both acidic and alkali conditions 
was found to be within the limits. Oxidative degradation studies were 
performed by using peroxide solution and the results showed that there 
was no degradation products formed. The drug solutions were placed in 
oven at 105 °C for 6 h for thermal stress studies and then injected into 
HPLC system and photo stress testing was carried out by keeping the 
drug solutions in UV chamber for 7 d. The purity of angle is found to be 
less than that of purity of threshold in all the conditions which indicates 
that the developed method was stability indicating. The forced 
degradation studies were performed without planning to recognize the 
degradation products but only to show that they are not interfering with 




Table 10: Degradation studies of
Sample name 
 ramipril, atorvastatin and clopidogrel 
Total purity Ramipril Atorvastatin Clopidogrel 
% of purity Purity of peak 
area 
% of purity Purity of peak 
area 
% of Purity Purity of peak 
area 
Acid 100 92.24 204612 92.20 500136 92.05 2439614 
base 100 93.42 204122 93.44 497716 93.12 2456551 
peroxide 100 94.05 205592 94.47 503765 94.09 2471387 
thermal 100 95.13 201373 95.60 497829 95.57 2441639 
uv 100 98.98 204288 98.68 501125 98.40 2459190 
Water 100 99.37 204177 99.32 500977 99.85 2452886 
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The current study describes new and simple, reliable, economic 
elution RP-HPLC-PDA method for the simultaneous estimation of 
ramipril, atorvastatin and clopidogrel. The forced degradation 
studies were conducted for the three drugs by using several 
degradation conditions like oxidation, acidic, alkali, thermal, and 
photolytic conditions and proposed method was effectively 
employed from the resolution of employed samples peaks. To our 
present knowledge, no such detailed and stability indicating method 
has been presented for the assay of this triplicate drug mixture. The 
developed method finished use of PAD as a tool for peak integrity 
and purity confirmation. Therefore the proposed study method can 
be used for quantification of ramipril, atorvastatin and clopidogrel in 
bulk and pharmaceutical dosage form. Finally, this method was 
carefully validated; as a result, it can be suggested for routine 
analysis and for testing quality through stability studies of the drugs.  
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